FibroGen saw the highest growth of 0.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of FibroGen‘s patent filings and grants. Buy the databook here.
FibroGen has been focused on protecting inventions in United States(US) with one publication in Q2 2024
The United States(US) Patent Office dominates the patent filings with nearly 50% of filings. The United States(US), and World Intellectual Property Organization(WIPO) patent Office are among the top ten patent offices where FibroGen is filings its patents..
Sanofi could be the strongest competitor for FibroGen
Kidney disease (nephropathy) related patents lead FibroGen portfolio followed by chronic kidney disease (chronic renal failure), and anemia
FibroGen has highest number of patents in kidney disease (nephropathy) followed by chronic kidney disease (chronic renal failure), anemia, anemia of chronic disease, and iron deficiency anemia.
For comprehensive analysis of FibroGen's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.